Pembrolizumab for metastatic melanoma in a renal allograft recipient with subsequent graft rejection and treatment response failure: a case report View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2017-12

AUTHORS

Vineet Kwatra, Narayan V. Karanth, Kelum Priyadarshana, Michail Charakidis

ABSTRACT

BACKGROUND: Transplant patients were excluded from the pivotal phase III trials of checkpoint inhibitors in metastatic melanoma. The efficacy and toxicity profiles of checkpoint inhibitors in this cohort of patients are not well described. To the best of our knowledge, this is the first case report of a renal transplant patient with stage IV melanoma treated with a programmed cell death protein 1 checkpoint inhibitor that led to both treatment failure and renal graft rejection. CASE PRESENTATION: We present a case of a 58-year-old white man with a long-standing cadaveric renal transplant who was diagnosed with a B-Raf Proto-Oncogene, Serine/Threonine Kinase wild-type metastatic melanoma. He was treated with first-line pembrolizumab but experienced subsequent graft failure and rapid disease progression. CONCLUSIONS: This case highlights the risks associated with the administration of checkpoint inhibitors in patients with a renal transplant and on immunosuppressive therapy. More specifically, it adds to the literature indicating that, compared with the cytotoxic T-lymphocyte-associated protein 4 inhibitor ipilimumab, anti-programmed cell death protein 1 agents are more likely to lead to renal graft failure. Additionally, these novel immunotherapeutics may be ineffective in transplant patients; therefore, clinicians should be very aware of those risks and carefully consider selection of agents and full disclosure of the risks to their patients. More... »

PAGES

73

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s13256-017-1229-z

DOI

http://dx.doi.org/10.1186/s13256-017-1229-z

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1084252384

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/28315636


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal, Humanized", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fatal Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Graft Rejection", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunosuppressive Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Ipilimumab", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kidney Failure, Chronic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kidney Transplantation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Melanoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Programmed Cell Death 1 Receptor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Proto-Oncogene Proteins B-raf", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Skin Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Failure", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Royal Darwin Hospital", 
          "id": "https://www.grid.ac/institutes/grid.240634.7", 
          "name": [
            "Medical Oncology Department, Alan Walker Cancer Centre, Royal Darwin Hospital, 105 Rocklands Drive, 0810, Tiwi, NT, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kwatra", 
        "givenName": "Vineet", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Royal Darwin Hospital", 
          "id": "https://www.grid.ac/institutes/grid.240634.7", 
          "name": [
            "Medical Oncology Department, Alan Walker Cancer Centre, Royal Darwin Hospital, 105 Rocklands Drive, 0810, Tiwi, NT, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Karanth", 
        "givenName": "Narayan V.", 
        "id": "sg:person.01262545403.17", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01262545403.17"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Flinders University", 
          "id": "https://www.grid.ac/institutes/grid.1014.4", 
          "name": [
            "NT Renal Services, Royal Darwin Hospital, Darwin, NT, Australia", 
            "Flinders University, Adelaide, SA, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Priyadarshana", 
        "givenName": "Kelum", 
        "id": "sg:person.015737237407.16", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015737237407.16"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Royal Darwin Hospital", 
          "id": "https://www.grid.ac/institutes/grid.240634.7", 
          "name": [
            "Medical Oncology Department, Alan Walker Cancer Centre, Royal Darwin Hospital, 105 Rocklands Drive, 0810, Tiwi, NT, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Charakidis", 
        "givenName": "Michail", 
        "id": "sg:person.0751251633.82", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0751251633.82"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1111/j.1432-2277.2008.00726.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003598072"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1600-6143.2010.03078.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006456042"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1600-6143.2010.03078.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006456042"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1503093", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014234053"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmc1509268", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015920152"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2013.49.2314", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020931173"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/ki.2010.97", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027017629", 
          "https://doi.org/10.1038/ki.2010.97"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/ajt.13711", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027688085"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/ndt/gfg1030", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030349545"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.imbio.2011.01.007", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040493603"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1504627", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052572745"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdw130", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1059394710"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4049/jimmunol.179.8.5204", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1077493695"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2017-12", 
    "datePublishedReg": "2017-12-01", 
    "description": "BACKGROUND: Transplant patients were excluded from the pivotal phase III trials of checkpoint inhibitors in metastatic melanoma. The efficacy and toxicity profiles of checkpoint inhibitors in this cohort of patients are not well described. To the best of our knowledge, this is the first case report of a renal transplant patient with stage IV melanoma treated with a programmed cell death protein 1 checkpoint inhibitor that led to both treatment failure and renal graft rejection.\nCASE PRESENTATION: We present a case of a 58-year-old white man with a long-standing cadaveric renal transplant who was diagnosed with a B-Raf Proto-Oncogene, Serine/Threonine Kinase wild-type metastatic melanoma. He was treated with first-line pembrolizumab but experienced subsequent graft failure and rapid disease progression.\nCONCLUSIONS: This case highlights the risks associated with the administration of checkpoint inhibitors in patients with a renal transplant and on immunosuppressive therapy. More specifically, it adds to the literature indicating that, compared with the cytotoxic T-lymphocyte-associated protein 4 inhibitor ipilimumab, anti-programmed cell death protein 1 agents are more likely to lead to renal graft failure. Additionally, these novel immunotherapeutics may be ineffective in transplant patients; therefore, clinicians should be very aware of those risks and carefully consider selection of agents and full disclosure of the risks to their patients.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/s13256-017-1229-z", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1038062", 
        "issn": [
          "1752-1947"
        ], 
        "name": "Journal of Medical Case Reports", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "11"
      }
    ], 
    "name": "Pembrolizumab for metastatic melanoma in a renal allograft recipient with subsequent graft rejection and treatment response failure: a case report", 
    "pagination": "73", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "006d8f3bc9b59adbaf1dc83f8d151ee4b983a5374cf1ba1ab67dac9df5e29235"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "28315636"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101293382"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s13256-017-1229-z"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1084252384"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s13256-017-1229-z", 
      "https://app.dimensions.ai/details/publication/pub.1084252384"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T09:30", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000346_0000000346/records_99802_00000004.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1186%2Fs13256-017-1229-z"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s13256-017-1229-z'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s13256-017-1229-z'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s13256-017-1229-z'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s13256-017-1229-z'


 

This table displays all metadata directly associated to this object as RDF triples.

197 TRIPLES      21 PREDICATES      58 URIs      38 LITERALS      26 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s13256-017-1229-z schema:about N03b65bcc175c4b1b877807d1dbfc5b4b
2 N074362c3c5f448b8943c3a2a3aa941c5
3 N0e004fd9bc8a4f35adad88acbb8ffb9d
4 N424b092c234e4fce8a282b6927a49ad8
5 N44703610ea6345cdad9ba37f69846b4b
6 N526f81ccc446409494e1a9856c769d75
7 N5300e09b3fff479eae384ec20c36aa2f
8 N57597979c8664e78b6cded2eca3d6917
9 N659100f43e1042fe9f4358b1ab012c9a
10 N67652c634d1c4042bbde3feed9513fef
11 N82f7b7256b1c499590d6f1c8c9854a00
12 N87f928e0cd9f43558c2ff917f070f302
13 N98cb31e187634388817e3bdf6f596fa1
14 Nbae9e3b381a04aa4b6a1405d5fdd3537
15 Nbce77c22b1ae4a85abf14e656a47be14
16 Nd16af0d5f7834e399d430a4a7e7c92a6
17 Nee9bc7c5ee7d4eea848aaf15f4f0f205
18 anzsrc-for:11
19 anzsrc-for:1103
20 schema:author N3126eced7dea4d6a98ed190b233b024a
21 schema:citation sg:pub.10.1038/ki.2010.97
22 https://doi.org/10.1016/j.imbio.2011.01.007
23 https://doi.org/10.1056/nejmc1509268
24 https://doi.org/10.1056/nejmoa1503093
25 https://doi.org/10.1056/nejmoa1504627
26 https://doi.org/10.1093/annonc/mdw130
27 https://doi.org/10.1093/ndt/gfg1030
28 https://doi.org/10.1111/ajt.13711
29 https://doi.org/10.1111/j.1432-2277.2008.00726.x
30 https://doi.org/10.1111/j.1600-6143.2010.03078.x
31 https://doi.org/10.1200/jco.2013.49.2314
32 https://doi.org/10.4049/jimmunol.179.8.5204
33 schema:datePublished 2017-12
34 schema:datePublishedReg 2017-12-01
35 schema:description BACKGROUND: Transplant patients were excluded from the pivotal phase III trials of checkpoint inhibitors in metastatic melanoma. The efficacy and toxicity profiles of checkpoint inhibitors in this cohort of patients are not well described. To the best of our knowledge, this is the first case report of a renal transplant patient with stage IV melanoma treated with a programmed cell death protein 1 checkpoint inhibitor that led to both treatment failure and renal graft rejection. CASE PRESENTATION: We present a case of a 58-year-old white man with a long-standing cadaveric renal transplant who was diagnosed with a B-Raf Proto-Oncogene, Serine/Threonine Kinase wild-type metastatic melanoma. He was treated with first-line pembrolizumab but experienced subsequent graft failure and rapid disease progression. CONCLUSIONS: This case highlights the risks associated with the administration of checkpoint inhibitors in patients with a renal transplant and on immunosuppressive therapy. More specifically, it adds to the literature indicating that, compared with the cytotoxic T-lymphocyte-associated protein 4 inhibitor ipilimumab, anti-programmed cell death protein 1 agents are more likely to lead to renal graft failure. Additionally, these novel immunotherapeutics may be ineffective in transplant patients; therefore, clinicians should be very aware of those risks and carefully consider selection of agents and full disclosure of the risks to their patients.
36 schema:genre research_article
37 schema:inLanguage en
38 schema:isAccessibleForFree true
39 schema:isPartOf N1f67969118824f8198158bff6331a6ca
40 N2a48770b983d4815b1b697c9cb756185
41 sg:journal.1038062
42 schema:name Pembrolizumab for metastatic melanoma in a renal allograft recipient with subsequent graft rejection and treatment response failure: a case report
43 schema:pagination 73
44 schema:productId N1daed5a250e0480090ee82ce68548586
45 N4b9fea5f9bc7471cadc69304749fd4b6
46 N625b2262d6af430c970919f91bd06fe2
47 N6319e3c1d00e47a3bb4e13fe73381f43
48 N7284601f7c754f02969d012926175532
49 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084252384
50 https://doi.org/10.1186/s13256-017-1229-z
51 schema:sdDatePublished 2019-04-11T09:30
52 schema:sdLicense https://scigraph.springernature.com/explorer/license/
53 schema:sdPublisher N773f5715640a42199ed4d423fae4b9e1
54 schema:url https://link.springer.com/10.1186%2Fs13256-017-1229-z
55 sgo:license sg:explorer/license/
56 sgo:sdDataset articles
57 rdf:type schema:ScholarlyArticle
58 N03b65bcc175c4b1b877807d1dbfc5b4b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
59 schema:name Ipilimumab
60 rdf:type schema:DefinedTerm
61 N074362c3c5f448b8943c3a2a3aa941c5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
62 schema:name Immunosuppressive Agents
63 rdf:type schema:DefinedTerm
64 N0e004fd9bc8a4f35adad88acbb8ffb9d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
65 schema:name Melanoma
66 rdf:type schema:DefinedTerm
67 N1daed5a250e0480090ee82ce68548586 schema:name nlm_unique_id
68 schema:value 101293382
69 rdf:type schema:PropertyValue
70 N1f67969118824f8198158bff6331a6ca schema:issueNumber 1
71 rdf:type schema:PublicationIssue
72 N2a48770b983d4815b1b697c9cb756185 schema:volumeNumber 11
73 rdf:type schema:PublicationVolume
74 N3126eced7dea4d6a98ed190b233b024a rdf:first N7d95584e6b174bcba25888cbbb710ff8
75 rdf:rest Nbc4b3cb86cbf4c3f9ad1d6c78e501c3d
76 N424b092c234e4fce8a282b6927a49ad8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
77 schema:name Kidney Transplantation
78 rdf:type schema:DefinedTerm
79 N44703610ea6345cdad9ba37f69846b4b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
80 schema:name Skin Neoplasms
81 rdf:type schema:DefinedTerm
82 N4b9fea5f9bc7471cadc69304749fd4b6 schema:name dimensions_id
83 schema:value pub.1084252384
84 rdf:type schema:PropertyValue
85 N526f81ccc446409494e1a9856c769d75 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
86 schema:name Graft Rejection
87 rdf:type schema:DefinedTerm
88 N5300e09b3fff479eae384ec20c36aa2f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
89 schema:name Middle Aged
90 rdf:type schema:DefinedTerm
91 N57597979c8664e78b6cded2eca3d6917 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
92 schema:name Treatment Failure
93 rdf:type schema:DefinedTerm
94 N625b2262d6af430c970919f91bd06fe2 schema:name readcube_id
95 schema:value 006d8f3bc9b59adbaf1dc83f8d151ee4b983a5374cf1ba1ab67dac9df5e29235
96 rdf:type schema:PropertyValue
97 N6319e3c1d00e47a3bb4e13fe73381f43 schema:name doi
98 schema:value 10.1186/s13256-017-1229-z
99 rdf:type schema:PropertyValue
100 N659100f43e1042fe9f4358b1ab012c9a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
101 schema:name Proto-Oncogene Proteins B-raf
102 rdf:type schema:DefinedTerm
103 N67652c634d1c4042bbde3feed9513fef schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
104 schema:name Male
105 rdf:type schema:DefinedTerm
106 N7284601f7c754f02969d012926175532 schema:name pubmed_id
107 schema:value 28315636
108 rdf:type schema:PropertyValue
109 N773f5715640a42199ed4d423fae4b9e1 schema:name Springer Nature - SN SciGraph project
110 rdf:type schema:Organization
111 N7d95584e6b174bcba25888cbbb710ff8 schema:affiliation https://www.grid.ac/institutes/grid.240634.7
112 schema:familyName Kwatra
113 schema:givenName Vineet
114 rdf:type schema:Person
115 N82f7b7256b1c499590d6f1c8c9854a00 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Programmed Cell Death 1 Receptor
117 rdf:type schema:DefinedTerm
118 N87f928e0cd9f43558c2ff917f070f302 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Fatal Outcome
120 rdf:type schema:DefinedTerm
121 N98cb31e187634388817e3bdf6f596fa1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name Antibodies, Monoclonal
123 rdf:type schema:DefinedTerm
124 Nb4da5abaac51424e84c21c4fddd1dfbe rdf:first sg:person.015737237407.16
125 rdf:rest Nb92e75acea1a449597da40d427b69e49
126 Nb92e75acea1a449597da40d427b69e49 rdf:first sg:person.0751251633.82
127 rdf:rest rdf:nil
128 Nbae9e3b381a04aa4b6a1405d5fdd3537 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Antineoplastic Agents
130 rdf:type schema:DefinedTerm
131 Nbc4b3cb86cbf4c3f9ad1d6c78e501c3d rdf:first sg:person.01262545403.17
132 rdf:rest Nb4da5abaac51424e84c21c4fddd1dfbe
133 Nbce77c22b1ae4a85abf14e656a47be14 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Humans
135 rdf:type schema:DefinedTerm
136 Nd16af0d5f7834e399d430a4a7e7c92a6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Kidney Failure, Chronic
138 rdf:type schema:DefinedTerm
139 Nee9bc7c5ee7d4eea848aaf15f4f0f205 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Antibodies, Monoclonal, Humanized
141 rdf:type schema:DefinedTerm
142 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
143 schema:name Medical and Health Sciences
144 rdf:type schema:DefinedTerm
145 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
146 schema:name Clinical Sciences
147 rdf:type schema:DefinedTerm
148 sg:journal.1038062 schema:issn 1752-1947
149 schema:name Journal of Medical Case Reports
150 rdf:type schema:Periodical
151 sg:person.01262545403.17 schema:affiliation https://www.grid.ac/institutes/grid.240634.7
152 schema:familyName Karanth
153 schema:givenName Narayan V.
154 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01262545403.17
155 rdf:type schema:Person
156 sg:person.015737237407.16 schema:affiliation https://www.grid.ac/institutes/grid.1014.4
157 schema:familyName Priyadarshana
158 schema:givenName Kelum
159 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015737237407.16
160 rdf:type schema:Person
161 sg:person.0751251633.82 schema:affiliation https://www.grid.ac/institutes/grid.240634.7
162 schema:familyName Charakidis
163 schema:givenName Michail
164 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0751251633.82
165 rdf:type schema:Person
166 sg:pub.10.1038/ki.2010.97 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027017629
167 https://doi.org/10.1038/ki.2010.97
168 rdf:type schema:CreativeWork
169 https://doi.org/10.1016/j.imbio.2011.01.007 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040493603
170 rdf:type schema:CreativeWork
171 https://doi.org/10.1056/nejmc1509268 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015920152
172 rdf:type schema:CreativeWork
173 https://doi.org/10.1056/nejmoa1503093 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014234053
174 rdf:type schema:CreativeWork
175 https://doi.org/10.1056/nejmoa1504627 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052572745
176 rdf:type schema:CreativeWork
177 https://doi.org/10.1093/annonc/mdw130 schema:sameAs https://app.dimensions.ai/details/publication/pub.1059394710
178 rdf:type schema:CreativeWork
179 https://doi.org/10.1093/ndt/gfg1030 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030349545
180 rdf:type schema:CreativeWork
181 https://doi.org/10.1111/ajt.13711 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027688085
182 rdf:type schema:CreativeWork
183 https://doi.org/10.1111/j.1432-2277.2008.00726.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1003598072
184 rdf:type schema:CreativeWork
185 https://doi.org/10.1111/j.1600-6143.2010.03078.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1006456042
186 rdf:type schema:CreativeWork
187 https://doi.org/10.1200/jco.2013.49.2314 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020931173
188 rdf:type schema:CreativeWork
189 https://doi.org/10.4049/jimmunol.179.8.5204 schema:sameAs https://app.dimensions.ai/details/publication/pub.1077493695
190 rdf:type schema:CreativeWork
191 https://www.grid.ac/institutes/grid.1014.4 schema:alternateName Flinders University
192 schema:name Flinders University, Adelaide, SA, Australia
193 NT Renal Services, Royal Darwin Hospital, Darwin, NT, Australia
194 rdf:type schema:Organization
195 https://www.grid.ac/institutes/grid.240634.7 schema:alternateName Royal Darwin Hospital
196 schema:name Medical Oncology Department, Alan Walker Cancer Centre, Royal Darwin Hospital, 105 Rocklands Drive, 0810, Tiwi, NT, Australia
197 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...